Federal Register Notice: FDA has determined the regulatory review period for Asthmatx, Inc.’s Alair Bronchial Thermoplasty System is 1,743 days for extending a patent which claims the medical device. The Alair system is indicated for treating severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long-acting beta agonists. To view this notice, click here.
